AroCell AB

Uppsala Business Park
Virdings allé 32 B
Uppsala
SE-754 50

Tel: 46-0-706-92-62-06

About AroCell AB

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders.
YEAR FOUNDED:
2003
LEADERSHIP:
CEO: Jan Stålemark
CFO: Ann Hammarstrand
PRODUCTS:
All Products

8 articles about AroCell AB

AroCell Signs Letter of Intent With Korean-Based Company, Green Cross Cell Corporation

11/22/2017

he companies have agreed to enter into a collaboration for the clinical development of TK 210 ELISA.
AroCell AB: Reporting Period 1 July - 30 September 2017

11/22/2017

Sales for the period were 0 (46). Expenses were 3,678 (2,590).
Arocell AB: Abstract Published Presenting Arocell TK 210 ELISA From the PROMIX Study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

11/8/2017

The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery.
AroCell AB: Announces That A Distribution Agreement Has Been Signed With Pathway Diagnostics, For Distribution Of The Arocell TK 210 ELISA Test In United Kingdom And Ireland

10/13/2017
AroCell AB Research Poster On TK1 / TK 210 ELISA In Prostate Cancer Has Been Accepted For Presentation At The UK National Cancer Research Institute (NCRI) Annual Meeting November 2017

9/26/2017
AroCell AB: TK 210 ELISA Abstract On In-Vitro Studies Of Cancer Drugs Has Been Accepted For Presentation At The National Cancer Research Institute (NCRI) UK Symposium

9/22/2017
New Application For AroCell AB TK 210 ELISA Opens New Opportunities For Drug Development Research

9/18/2017
AroCell AB: Interim Report, Q2 2017

8/24/2017